Dr. Reddy’s Recalls Mislabelled Levetiracetam Injection in U.S.

Dr Reddy’s Laboratories ( (RDY) ) has issued an announcement.

On March 13, 2025, Dr. Reddy’s Laboratories announced a nationwide recall in the U.S. of a batch of Levetiracetam in 0.75% Sodium Chloride Injection due to mislabeling. The infusion bags were incorrectly labeled, posing a risk of patients receiving double the intended dose, potentially leading to serious side effects. The recall affects products distributed between November 4 and November 6, 2024, and involves notifying distributors and customers to return the affected products. The recall is conducted with the knowledge of the U.S. FDA, and no adverse events have been reported so far.

More about Dr Reddy’s Laboratories

Dr. Reddy’s Laboratories Ltd. is a global pharmaceutical company headquartered in Hyderabad, India, established in 1984. The company is committed to providing access to affordable and innovative medicines, offering a portfolio that includes APIs, generics, branded generics, biosimilars, and OTC products. Its major therapeutic areas include gastrointestinal, cardiovascular, diabetology, oncology, pain management, and dermatology, with significant markets in the USA, India, Russia & CIS countries, China, Brazil, and Europe.

YTD Price Performance: -20.04%

Average Trading Volume: 1,832,963

Technical Sentiment Consensus Rating: Hold

Current Market Cap: $10.68B

Find detailed analytics on RDY stock on TipRanks’ Stock Analysis page.